Key result
Droxidopa use in patients with neurogenic orthostatic hypotension reduced the proportion of patients reporting falls at one month compared to baseline (43.0% vs. 54.1%; P=0.0039).
Why the study?
Droxidopa is approved for symptomatic neurogenic orthostatic hypotension, but information regarding its effects on symptoms, outcomes, and quality of life beyond two weeks of treatment is limited.
Does droxidopa reduce fall frequency and improve patient-reported outcomes in adult patients with symptomatic neurogenic orthostatic hypotension over 6 months?
Population
179 patients who recently started droxidopa for nOH
Comparison
Droxidopa treatment assessed over time vs baseline
Design
Non-interventional US-based prospective cohort study
Follow-up
Six months
Authors
Loading...
Droxidopa may reduce falls in nOH beyond short-term use; leaves open whether benefits persist in randomized long-term trials.
Cohort (n=179)
Does droxidopa reduce fall frequency and improve patient-reported outcomes in adult patients with symptomatic neurogenic orthostatic hypotension over 6 months?
Absolute Event Rate: 43% vs 54.1%
p-value: p=0.0039
Real-world use of droxidopa for neurogenic orthostatic hypotension is associated with sustained reductions in fall frequency and improvements in patient-reported quality of life over 6 months.
François et al. (2019) conducted a cohort in symptomatic neurogenic orthostatic hypotension (nOH) (n=179). Droxidopa vs. Baseline was evaluated on Proportion of patients reporting falling at least once at one month (p=0.0039). Droxidopa use in patients with neurogenic orthostatic hypotension reduced the proportion of patients reporting falls at one month compared to baseline (43.0% vs. 54.1%; P=0.0039).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: